Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis
Sponsor: Avanir Pharmaceuticals
Listed as NCT01324232, this PHASE2 trial focuses on Central Neuropathic Pain and Multiple Sclerosis and remains completed. Sponsored by Avanir Pharmaceuticals, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avanir Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .